CINCINNATI, June 7, 2011 /PRNewswire/ -- Kendle (Nasdaq:
KNDL), a leading, global full-service clinical research
organization (CRO), today announced the appointment of Pierre Geoffroy, MD, CM, MSc, FCFP as Vice
President, Early Stage, effective immediately. Dr. Geoffroy
brings nearly two decades of clinical development experience to
this key leadership position. He will oversee the development
of Early Stage programs for customers worldwide, providing medical
expertise and clinical insights for the development of safe and
effective early stage clinical trials. Dr. Geoffroy will be
based out of Kendle's Early Stage unit in Toronto and will report directly to
Stephen Cutler, PhD, President and
CEO.
"We are thrilled to welcome Dr. Geoffroy to Kendle," said Dr.
Cutler. "He brings extensive expertise in early stage
development to assist our customers in making strategic decisions
related to the future of their compounds. We look forward to
his leadership as we focus on positioning Kendle's Early Stage
operations for growth."
Dr. Geoffroy joins Kendle from Lambda Therapeutic Research Inc.
where he served most recently as Chief Medical Officer, Vice
President and Principal Investigator. He also has served in
senior clinical roles at multiple global biopharmaceutical
corporations, including Senior Director, Clinical at Sanofi
Pasteur; Head of Clinical Research and Senior Advisor, Drug
Development at Wyeth Ayerst K.K.; Regional Director, Wyeth Research
Canada; Executive Director, Medical Affairs at Hoffmann La Roche;
and Associate Medical Director at SmithKline Beecham.
Dr. Geoffroy earned his medical degree, a Master of Science
degree in Epidemiology and a Bachelor of Science in Nutrition, from
McGill University. He also holds
a Master of Science in Nutrition from the University of Toronto. He is certified by the
Corporation des Medecins du Quebec, the College of Family
Physicians of Canada, the Medical
Council of Canada and the College
of Physicians and Surgeons of Ontario. He was awarded a fellowship in
the College of Family Physicians of Canada in 1995.
Kendle has more than 25 years of experience in conducting Early
Stage studies for more than 170 customers worldwide. The
Company's Early Stage operations consist of an 86-bed
state-of-the-art inpatient unit in Toronto and a bioequivalence unit in
Morgantown, W.Va. with bed space
for 118 patients, allowing up to five bioequivalence studies to be
conducted simultaneously. The Toronto unit is experienced
across all therapeutic areas and recognized internationally by
global regulatory authorities for its expertise in conducting human
abuse liability studies. The unit houses the world's largest
database of recreational drug users, ensuring that study
participants can be enrolled rapidly and efficiently into these
unique studies.
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is a leading global
clinical research organization providing the full range of early-
to late-stage clinical development services for the world's
biopharmaceutical industry. Our focus is on innovative
solutions that reduce cycle times for our customers and accelerate
the delivery of life-enhancing products to market for the benefit
of patients worldwide. As one of the world's largest global
providers of Phase I-IV services, we offer experience spanning more
than 100 countries, along with industry-leading patient access and
retention capabilities and broad therapeutic expertise, to meet our
customers' clinical development challenges.
For more information, please visit www.kendle.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, statements relating to Dr.
Geoffroy's anticipated contribution to Kendle's Early Stage
operations growth. Words such as "anticipate," "believe," "plan,"
"estimate," "expect," "intend," "will," "should," "may," and other
similar expressions are intended to identify forward-looking
statements. Such statements are based upon the current beliefs and
expectations of Kendle's management and involve a number of
significant risks and uncertainties, many of which are difficult to
predict and are generally beyond the control of Kendle. Actual
results may differ materially from the results anticipated in these
forward-looking statements. Additional factors that could cause
Kendle's results to differ materially from those described in the
forward-looking statements can be found in the periodic reports
filed with the Securities and Exchange Commission, which are
available at the Securities and Exchange Commission's website
(http://www.sec.gov) at no charge. Kendle assumes no responsibility
to update any forward-looking statements as a result of new
information or future developments except as expressly required by
law.
SOURCE Kendle International Inc.